( June 26, 2025, 9:33 AM EDT) -- TAMPA, Fla. — Novo Nordisk Inc. fails to “meet a high bar to alter or amend a judgment” under Federal Rule of Civil Procedure 59(e) for a Florida federal court to amend its order granting summary judgment in favor of a pharmaceutical company accused of selling unapproved compounded drugs containing semaglutide XE "semaglutide" , the company says in an opposition brief....